论文部分内容阅读
尼达尼布是用于特发性肺纤维化治疗的小分子化学药物,作为一种可抑制血管生成和组织纤维化的多靶点受体酪氨酸激酶抑制剂,近年大量研究表明尼达尼布具有较好的抗肿瘤作用,其与抗肿瘤药物联用可提高抗肿瘤疗效。文章通过查阅文献及临床研究报告,对尼达尼布的临床前抑瘤作用及在多种肿瘤治疗中的临床试验研究进行了综述,为尼达尼布进一步的抗肿瘤研究开发提供参考。
Nindabi is a small molecule chemical for the treatment of idiopathic pulmonary fibrosis. As a multi-target tyrosine kinase inhibitor that inhibits angiogenesis and tissue fibrosis, a large number of studies have shown that Nida Nib has a good anti-tumor effect, which in combination with anti-cancer drugs can improve anti-tumor efficacy. The article reviews the literatures and clinical research reports, summarizes the preclinical antitumor effects of nindabu and clinical trials in various tumor treatments, and provides a reference for further antitumor research and development of nintedanib.